Detalhe da pesquisa
1.
Cardiovascular benefits of SGLT2 inhibitors in type 2 diabetes, interaction with metformin and role of erythrocytosis: a self-controlled case series study.
Cardiovasc Diabetol
; 21(1): 92, 2022 06 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35658864